Meteospasmyl

Alverine citrate, the active ingredient in Meteospasmyl, is an antispasmodic presented as an oral dosage form for oral use. It is combined with simethicone to relieve abdominal discomfort, intestinal spasm and excess gas in adults. GNH USA supplies Meteospasmyl as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Meteospasmyl is an antispasmodic/antiflatulent used in functional gastrointestinal disorders. - Abdominal pain: reduces pain caused by intestinal muscle spasm. - Intestinal spasm: relaxes smooth muscle to ease cramping. - Flatulence: facilitates the elimination of gas trapped in the gut. - Irritable bowel syndrome: helps control recurrent abdominal discomfort and bloating.

Adverse reactions may occur with any medication and should be monitored.

Common Side Effects: - Dry mouth: mild reduction in salivary flow. - Nausea: transient feeling of queasiness. - Headache: mild to moderate intensity. - Dizziness: occasional light‑headed sensation. - Diarrhoea: loose stools in some users. - Abdominal discomfort: mild irritation.

Serious or Rare Side Effects: - Allergic reaction: rash, itching, swelling, or difficulty breathing. - Severe abdominal pain: persistent or worsening pain. - Hepatic dysfunction: abnormal liver enzymes (rare). - Cardiac arrhythmia: irregular heartbeat reported rarely. - Anaphylaxis: life‑threatening hypersensitivity (extremely rare).

Before using Meteospasmyl, consider the following safety measures. - Pregnancy: consult a healthcare professional; safety data are limited. - Breastfeeding: discuss potential risks with a physician. - Liver disease: use with caution; monitor hepatic function. - Renal impairment: dose adjustment may be required. - Concomitant anticholinergics: may increase antispasmodic effect. - Store at ambient temperature: keep below 25 °C, retain in original packaging, protect from moisture.

Meteospasmyl may interact with other medicines; awareness helps avoid adverse outcomes.

Major Interactions (Avoid): - Monoamine oxidase inhibitors (MAOIs): risk of heightened anticholinergic effects. - Strong anticholinergic agents: may potentiate dry‑mouth and constipation.

Moderate Interactions (Monitor Closely): - Other antispasmodics: additive smooth‑muscle relaxation. - Proton‑pump inhibitors: possible alteration of gastric pH affecting absorption. - Antihistamines: may increase sedation or dizziness. - Herbal preparations containing belladonna: could enhance anticholinergic load.